Diabetes

November 18, 2017

Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, attenuates diabetic nephropathy, insulin resistance and hypertension and extends life span via up regulation of its target gene, 18/November/2017, 8.03 am

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and […]
November 16, 2017

Molecular therapy for glucose homeostasis and TIIDM: Butylphthalide (3-n-butylphthalide or NBP), found in celery oil,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/November/2017, 5.59 am

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, […]
November 14, 2017

Molecular therapy for middle aged TIIDM patients: Fidarestat,an alodose reductase inhibitor used to control diabetic complications, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 15/November/2017, 5.26 am

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD […]
November 14, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Victoza/Saxenda, a drug used in the treatment of TIIDM and Obesity,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 15/September/2017, 5.14 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]